02.14.25 -- Companies To Watch: Senti Bio

From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, joins the Business of Biotech to discuss his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. From mastering in-house manufacturing to forging strategic partnerships, Capsida aims to redefine genetic medicine. Listen now!

Learn how home visits enhance the patient experience in rare disease studies and how sponsors can use mobile research nurses to reach more rare disease patients and keep them in clinical trials longer.

Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development.

Tune Therapeutics will launch the first human trial of an epigenetic therapy, TUNE-401, targeting chronic Hepatitis B, a major global health threat affecting millions.

Automation has become an essential tool for addressing the inefficiencies in traditional clinical trial methodologies, enabling trial teams to instead concentrate on critical tasks such as patient care.